Incyte Corporation
NASDAQ:INCYBiotechnology
-$0.77 today
- Market cap
- $24.01B
- Beta
- 0.79
- P/E (TTM)
- 13.7
- EPS (TTM)
- $7.18
Volume 1.21M
Average 1.58M
INCY Purchases of Investments
Cash used to buy marketable securities and other investments.
Incyte CorporationNASDAQ: INCY
Purchases of Investments · Q2 FY2026 · quarter ended Jun 2026
Purchases of investments grows, but more slowly than its trailing trend
Q2 FY2026 purchases of investments of $71.38M (cash outflow) rose 27.2% year over year, behind the +177.1% change in trailing-twelve-month purchases of investments. Sequentially, it fell 50.0% from the prior quarter. Over 3 fiscal years it compounded at +56.0% a year.
Context
- Purchases of investments amounted to 5.9% of revenue in FY2025, down 0.2 pp from a year earlier.
- Purchases of investments grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +27.2% toward the trailing-twelve-month pace of +177.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (303.38M) USD
- Year-over-year change
- -17.4%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (303.38M) | -17.4% |
| FY2024 | 2024-12-31 | (258.37M) | +44.6% |
| FY2023 | 2023-12-31 | (466.02M) | -483.5% |
| FY2022 | 2022-12-31 | (79.86M) | +70.3% |
| FY2021 | 2021-12-31 | (268.68M) | — |
Purchases of Investments vs competitors
How INCY compares with its peers on the latest reported figures
- INCY's LTM Jun 2026 purchases of investments of $420.12M is the 7th largest of the 11 companies compared; the peer median is $515.21M.
- Its year-over-year change of +177.1% is the 2nd highest of 8, against a peer median of -14.0%.
- Purchases of investments amounts to 7.2% of revenue for INCY, versus a peer median of 44.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10.27B | -14.0% | +13.5% | 66.1% | |
| LTM Jun 2026 | $864.57M | +285.2% | +142.5% | 297.6% | |
| LTM Jul 2026 | $686.99M | -29.1% | -24.2% | 28.2% | |
| LTM Sep 2026 | $606.54M | -87.5% | +90.9% | 44.6% | |
| LTM Aug 2026 | $604.34M | +4.3% | +23.9% | 86.1% | |
| LTM Jun 2026 | $426.07M | — | -53.2% | 10.3% | |
| LTM Jun 2026 | $420.12M | +177.1% | +56.0% | 7.2% | |
| LTM Mar 2026 | $327.5M | +60.6% | — | — | |
| LTM Mar 2026 | $130.83M | -81.7% | -14.5% | — | |
| LTM Mar 2026 | $16.02M | — | — | 32.3% | |
| LTM Sep 2026 | $0 | — | — | — | |
| Peer median (excluding INCY) | $515.21M | -14.0% | +13.5% | 44.6% | |
Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 948.58M | 340.66M | 597.6M | 32.62M | 1.29B |
| Depreciation & Amortization | 57.84M | 67.86M | 82.66M | 89.25M | 93.29M |
| Deferred Income Tax | (465.6M) | 57.09M | (158.9M) | (85.55M) | 247.69M |
| Stock-Based Compensation | 183.01M | 188.42M | 215.89M | 266.06M | 249.35M |
| Change in Working Capital | (14.57M) | 198.81M | (248.65M) | 138.24M | (527.16M) |
| Accounts Receivables | (134.31M) | (28.58M) | (98.68M) | (111.59M) | (170.77M) |
| Inventory | (20.97M) | (67.5M) | (170.15M) | (127.63M) | (58.51M) |
| Accounts Payables | 73.34M | 105.44M | (167.95M) | 88.16M | 6.56M |
| Other Working Capital | 67.36M | 189.46M | 188.12M | 289.3M | (304.44M) |
| Other Non-Cash Items | 40.23M | 117.11M | 7.89M | (105.28M) | 63.69M |
| Operating Cash Flow | 749.49M | 969.94M | 496.49M | 335.34M | 1.41B |
| Capital Expenditures | (181.01M) | (77.83M) | (32.49M) | (86.26M) | (58.87M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (268.68M) | (79.86M) | (466.02M) | (258.37M) | (303.38M) |
| Sales of Investments | 241.98M | 79.15M | 305.83M | 516.05M | 284.64M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (207.7M) | (78.54M) | (207.68M) | 157.52M | (102.61M) |
| Debt Repayment | (2.42M) | (2.86M) | (3.36M) | (3.8M) | (4.54M) |
| Common Stock Issued | 58.63M | 61.12M | 35.84M | 49.3M | 221.76M |
| Common Stock Repurchased | 0 | 0 | 0 | (2B) | (19.1M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50.03M) | (59.05M) | (52.51M) | (62.26M) | (97.08M) |
| Financing Cash Flow | 6.18M | (794K) | (20.03M) | (2.02B) | 101.04M |
| Effect of Forex Changes | (3.53M) | 3.38M | (6.82M) | 3.15M | (1.94M) |
| Net Change in Cash | 544.43M | 893.98M | 261.95M | (1.53B) | 1.41B |
| Free Cash Flow | 568.48M | 892.11M | 464M | 249.07M | 1.35B |
Incyte Corporation
NASDAQ:INCY
Intrinsic Alpha fair value
Locked
Current Price
$117.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.